L
Lung Pacer
Lungpacer Medical Inc is developing a novel therapeutic solution for preserving the integrity and strength of the diaphragm muscle
About Lung Pacer
Lungpacer Medical Inc. is a pioneering medical technology company specializing in diaphragm pacing therapy aimed at enhancing respiratory function in critically ill patients. The company operates within the healthcare and medical device market, focusing on hospitals and healthcare providers as its primary clients. Lungpacer's core product, the Lungpacer Diaphragm Pacing Therapy System, is designed to stimulate the diaphragm, thereby improving breathing in patients who are dependent on mechanical ventilation. This innovative solution addresses a critical need in intensive care units (ICUs) by potentially reducing the duration of mechanical ventilation and associated complications.
Lungpacer's business model is based on the development, regulatory approval, and commercialization of its medical devices. Revenue is generated through the sale of these devices to hospitals and healthcare facilities. The company leverages its strong intellectual property portfolio, which includes numerous patents, to maintain a competitive edge in the market.
The company is led by a seasoned management team with extensive experience in the medical device industry. Doug Evans, the CEO, brings over 30 years of industry experience and a track record of successful product development and commercialization. The leadership team also includes experts in medical product development and commercialization, ensuring that Lungpacer is well-positioned to bring its innovative solutions to market.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2009
- Headquarters
- Burnaby, Canada
- Employees
- 58
- Open positions
- 1
- Dealroom signal
- 50.7/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Apr 2022 | $20M | $80M | WJFS | — |
| EARLY VCOther financing | Jan 2021 | $16M | $64M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Lung Pacer is 2K monthly website visits, up 53.8% over the last three months. Lung Pacer's team grew 13.7% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
National Research Council Canada
Keiretsu Forum
Keiretsu Capital
KCK Global
Series A1 investor entered at this stage
WJFS
Other known investors2 additional known investors
NEA
Simon Fraser University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Lung Pacer on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Lung Pacer’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.